ArticleCureus2026
Seroprevalence and Temporal Trends of Syphilis Among Blood Donors at Dhiraj Blood Bank in Waghodia, Gujarat, India: A Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSyphilis remains an important transfusion-transmitted infection (TTI) despite improvements in donor selection and blood screening practices. Continuous surveillance among blood donors is essential for ensuring transfusion safety and monitoring disease trends.
objectiveTo determine the seroprevalence and temporal trends of syphilis among blood donors at a tertiary care blood bank in Gujarat, India. MATERIALS AND
methodA retrospective, record-based cross-sectional study was conducted at Dhiraj Blood Bank, Dhiraj General Hospital, Waghodia, Gujarat, India. Blood donor records from January 2023 to July 2025 were reviewed. All eligible voluntary and replacement blood donors who underwent routine screening were included. Initial screening for syphilis was performed using the Venereal Disease Research Laboratory test (VDRL), and reactive samples were confirmed using Syphi Microlisa, a qualitative enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to
resultsA total of 7,471 blood donations were screened during the study period. 111 (1.49%) samples were reactive by VDRL, of which 45 (40.5%) were reactive on Syphi Microlisa, yielding an overall syphilis seroprevalence of 0.60%. The annual seroprevalence was 0.85% in 2023, 0.08% in 2024, and 0.90% in 2025 (up to July), showed variation across the study years. More than half of the VDRL-reactive samples were non-reactive on Syphi Microlisa, highlighting the importance of appropriate second-step treponemal testing.
conclusionSyphilis continues to be detected among apparently healthy blood donors, emphasizing the need for sustained donor screening and surveillance. The combined use of VDRL and confirmatory ELISA improves diagnostic accuracy and supports safe transfusion practices. Regular monitoring of seroprevalence trends and strengthening blood safety measures remain essential for preventing TTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.